Impact of faecal haemoglobin concentration on colorectal cancer mortality and all-cause death

BMJ Open

Volumn 3, Issue 11, 2013, Pages

  Chen, Li Sheng ^a   Yen, Amy Ming Fang ^a   Fraser, Callum G ^b   Chiu, Sherry Yueh Hsia ^c   Fann, Jean Ching Yuan ^d   Wang, Po En ^e   Lin, Sheng Che ^f   Liao, Chao Sheng ^g   Lee, Yi Chia ^h   Chiu, Han Mo ^h   Chen, Hsiu Hsi ⁱ  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d KAINAN UNIVERSITY   (Taiwan)

^e Keelung City Public Health Bureau   (Taiwan)

^f Tainan City Health Bureau   (Taiwan)

^g SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

ⁱ NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FECES HEMOGLOBIN; HEMOGLOBIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CAUSE OF DEATH; COLORECTAL ADENOMA; COLORECTAL CANCER; DIABETES MELLITUS; FECES LEVEL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY;

EID: 84888119215     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003740     Document Type: Article

References (28)

1. Towler B, Irwig L, Glasziou P, et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998;317:559-65. (Pubitemid 28395924)
2. Hewitson P, Glasziou P, Irwig L, et al. Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Syst Rev 2007; (1): CD001216.
3. Young GP, Fraser CG, Halloran SP, et al. Guaiac-based faecal occult blood testing for colorectal cancer screening: an obsolete strategy? Gut 2012;61:959-60.
4. Fraser CG. A future for faecal haemoglobin measurements in the medical laboratory. Ann Clin Biochem 2012;49:518-26.
5. Halloran SP, Launoy G, Zappa M. Faecal occult blood testing. In: Segnan N, Patnick J, von Karsa L, eds. European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st edn. Luxembourg: International Agency for Research on Cancer, Publications Office of the European Union, 2010:103-14.
6. Duffy MJ, Van Rossum L G M, Van Turenhout ST, et al. Use of faecal markers in screening for colorectal neoplasia: a European Group on Tumor Markers (EGTM) position paper. Int J Cancer 2011;128:3-11.
7. Rabeneck L, Rumble RB, Thompson F, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012;26:131-47.
8. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-55. (Pubitemid 351650610)
9. Fraser CG, Mathew CM, McKay K, et al. Automated immunochemical quantitation of haemoglobin in faeces collected on cards for screening for colorectal cancer. Gut 2008;57:1256-60.
10. Ciatto S, Martinelli F, Castiglione G, et al. Association of FOBT-assessed f-Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 2007;96:218-21. (Pubitemid 46160624)
11. Chen LS, Yen AM, Chiu SY, et al. Baseline fecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 2011;12:551-8.
12. Chen T H H, Chiu YH, Luh DL, et al. Taiwan Community-based Integrated Screening Group. Community-based multiple screening model: design, implementation, and analysis of 42, 387 participants. Cancer 2004;100:1734-43.
13. Yang KC, Liao CS, Chiu YH, et al. Colorectal cancer screening with fecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan. J Med Screen 2006;13:S8-13.
14. Chen LS, Liao CS, Chang SH, et al. Cost-effectiveness analysis for determining optimal cut-off of immunochemical fecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen 2007;14:191-9.
15. Flitcroft KL, St John DJ, Howard K, et al. A comparative case study of bowel cancer screening in the UK and Australia: evidence lost in translation? J Med Screen 2011;18:193-203.
16. Park MJ, Choi KS, Lee YK, et al. A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program. Scand J Gastroenterol 2012;47:461-6.
17. Zorzi M, Fedato C, Grazzini G, et al. High sensitivity of five colorectal screening programmes with faecal immunochemical test in the Veneto Region, Italy. Gut 2011;60:944-9.
18. Lee KJ, Inoue M, Otani T, et al. Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan. Cancer Detect Prev 2007;31:3-11. (Pubitemid 46367446)
19. Van Roon AH, Goede SL, Van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2013;62:409-15.
20. Quintero E, Castells A, Bujanda L, et al. COLONPREV Study Investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697-706.
21. Fraser CG. Screening for colorectal neoplasia with faecal tests. Lancet Oncol 2011;12:516-17.
22. Barrows GH, Burton RM, Jarrett DD, et al. Immunochemical detection of human blood in feces. Am J Clin Pathol 1978;69:342-6. (Pubitemid 8306794)
23. Wu TH, Lee TK, Yen MF, et al. Long-term mortality assessment using biological measures among elderly people. Ten-year follow-up of 597 healthy elderly subjects in Taiwan. Fam Pract 2002;19:272-7.
24. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999;91:916-32. (Pubitemid 29272518)
25. Nikiteas NI, Tzanakis N, Gazouli M, et al. Serum IL-6, TNF-alpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005;11:1639-43. (Pubitemid 40520804)
26. Groblewska M, Mroczko B, Wereszczynska-Siemiatkowska U, et al. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 2008;46:1423-8.
27. Kim S, Keku TO, Martin C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008;68:323-8. (Pubitemid 351380135)
28. McDonald PJ, Strachan JA, Digby J, et al. Faecal haemoglobin concentrations by gender and age: implications for population-based screening for colorectal cancer. Clin Chem Lab Med 2012;50:935-40.